Skip to main content

Lee Zou

George Barth Geller Distinguished Professor
Pharmacology & Cancer Biology

Selected Grants


Mechanisms of APOBEC3A-induced cancer evolution and cancer vulnerability

ResearchPrincipal Investigator · Awarded by Massachusetts General Hospital · 2024 - 2029

Understanding and targeting the DNA replication stress in cancer cells

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2028

Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer

ResearchPrincipal Investigator · Awarded by Massachusetts General Hospital · 2023 - 2026

Uncovering novel vulnerabilities to treat SCLC therapy resistance

ResearchCollaborator · Awarded by Lung Cancer Research Foundation · 2023 - 2025

Dissecting early pathogenesis of BRCA1/2-associated cancer for risk prediction and prevention

ResearchPrincipal Investigator · Awarded by Massachusetts General Hospital · 2023 - 2025

Genetic and Genomics Training Grant

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2020 - 2025

Mechanisms of replication fork protection and recovery

ResearchPrincipal Investigator · Awarded by Washington University in St. Louis · 2023 - 2025

Understanding and targeting RNA/transcription-dependent DNA repair in cancer cells

ResearchUnit Director · Awarded by National Institutes of Health · 2022 - 2023

External Relationships


  • Bristol Myers Squibb
  • Chinese Biological Investigators Society
  • Cold Spring Harbor Asia
  • Duke -National Univeristy of Singapore
  • Institute of Biophysics, Chinese Academy of Science
  • Institute of Life Sciences, Zhejiang University
  • Massachusetts General Hospital (Partners Healthcare)
  • National Institute of Health
  • Pfizer Inc.
  • Sirrona Therapeutics, Inc
  • Society of Chinese Bioscientists in America
  • The Knut and Alice Wallenberg Foundation
  • The New Cornerstone Investigator Program
  • Washington University in St. Louis

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.